Loading
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Latest quote
$84.11
−$0.30 · -0.36%
After-hours
$84.11
$0.00 · 0.00%
Oct 9, 7:30 PM ET
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
88
Deep Value
Sentiment
66
Bullish
Risk
40
Moderate Risk
Momentum
56
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Day range
Current $84.11
52-week range
Current $84.11
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 4.66B USD | 4.03B USD | 3.62B USD | 2.91B USD | 2.45B USD |
| Cost of goods sold | 1.86B USD | 1.59B USD | 1.33B USD | 1.03B USD | 768M USD |
| Gross profit | 2.8B USD | 2.44B USD | 2.29B USD | 1.88B USD | 1.68B USD |
| Research and development | 599.1M USD | 552.4M USD | 505.8M USD | 484.2M USD | 604.2M USD |
| Selling, general, and administrative | 1.29B USD | 1.29B USD | 1.19B USD | 1.01B USD | 810.5M USD |
| Operating expenses | 1.89B USD | 1.84B USD | 1.69B USD | 1.49B USD | 1.41B USD |
| Interest income | 112.7M USD | 134.2M USD | 135M USD | 23.8M USD | 1.7M USD |
| Interest expense | 18.3M USD | 19M USD | 20.3M USD | 18.6M USD | 18.8M USD |
| Depreciation and amortization | 251.8M USD | 217.7M USD | 186M USD | 155.9M USD | 102M USD |
| Operating income | 911.8M USD | 600M USD | 597.7M USD | 391.2M USD | 265.8M USD |
| Net income | 836.3M USD | 576.2M USD | 541.5M USD | 341.2M USD | 216.9M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$95.07
13.03% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 13, 2022 | 4:1 | — | — |
Effective Jun 13, 2022
4:1
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P 500 ETF1557.T61.62B0.05%129.69T JPY0.09%¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI1.12B0.05%2.3T USD0.03%$381.94+0.63%
Vanguard S&P 500 ETFVOO933.6M0.05%1.8T USD0.03%$715.59+0.61%
Vanguard Morningstar Mid-Cap ETFVO760.04M0.33%226.4B USD0.03%$81.14+0.92%
Invesco QQQ Trust, Series 1QQQ660.49M0.13%506.92B USD0.18%$751.27+0.49%
Vanguard Morningstar Growth ETFVUG446.59M0.12%384.6B USD0.03%$91.97+0.72%
iShares Core S&P 500 ETFIVV423.45M0.05%897.2B USD0.03%$781.97+0.60%
State Street SPDR S&P 500 ETFSPY389.38M0.05%821.54B USD0.09%$778.57+0.60%State Street SPDR S&P 500 ETF1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOVanguard Morningstar Mid-Cap ETFVOInvesco QQQ Trust, Series 1QQQVanguard Morningstar Growth ETFVUGiShares Core S&P 500 ETFIVVState Street SPDR S&P 500 ETFSPYAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
